Sunitinib in Patients with Pre-Treated Pancreatic Neuroendocrine Tumors: A Real-World Study

#2065

Introduction: Besides data reported in a Phase-III trial, data on sunitinib in pancreatic Neuroendocrine Tumors (panNETs) are scanty.

Aim(s): To evaluate sunitinib efficacy and tolerability in panNETs patients treated in a real-world setting

Materials and methods: Retrospective analysis of advanced, progressive panNETs treated with sunitinib. Efficacy was assessed by evaluating progression-free survival, overall survival, and disease control (DC) rate (stable disease (SD) + partial response + complete response). Data are reported as median (25th – 75th IQR).

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Rinzivillo M

Authors: Rinzivillo M, Gritti S, Pusceddu S, Spallanzani A, Ibrahim T,

Keywords: Sunitinib, neuroendocrine tumors, pancreas, progressive disease, target therapy,